SCHEMBL3016487

SCHEMBL3016487

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(CBr)cc4)CC3)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 3/20 0.49
TSHR P16473 1/20 0.49
PKM P14618 2/20 0.49
NPC1 O15118 1/20 0.49
PKLR P30613 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 3/20 0.47
POLB P06746 3/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
HSD11B1 P28845 2/20 0.45
TP53 P04637 1/20 0.44
HTT P42858 2/20 0.44
GBA1 P04062 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004528 0.95 PKM (0.54) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3017677 0.92 USP2 (0.50) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3002345 0.92 USP2 (0.49) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3013112 0.91 KMT2A (0.52) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3011855 0.91 KMT2A (0.52) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3006461 0.90 MEN1 (0.49) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3007698 0.90 MAPT (0.61) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3010397 0.90 ALDH1A1 (0.59) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3006734 0.90 MAPT (0.56) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3015956 0.89 SMN1; SMN2 (0.47) USP2SMN1; SMN2LMNATSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.